Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qushi Huayu Decoction (QHD) is a traditional Chinese herbal formula composed of five herbs in specific ratios: Artemisiae scopariae herba (Yinchen), Polygoni cuspinati rhizome et radix (Huzhang), Herba hyperici japonica (Tianjihuang), Curcumae longae rhizome (Jianghuang), and Gardeniae fructus (Zhizi)[6]. It has been clinically used for the prevention and treatment of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)[1][2][3][4][5]. QHD exerts its effects through multiple mechanisms, including activation of AMP-activated protein kinase (AMPK) signaling, modulation of gut microbiota composition, regulation of lipid metabolism pathways such as SREBP-1 and ChREBP, inhibition of hepatic lipid accumulation, reduction in serum LDL cholesterol and liver enzymes, suppression of inflammatory mediators like tumor necrosis factor-alpha, and enhancement of fatty acid β-oxidation via JAK2/STAT3/CPT-1A pathway[1][2][4][5][8]. The formula contains active compounds such as emodin from Huzhang[6], along with various organic acids, iridoids, flavones, naphthols, anthraquinones[7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on qushi huayu decoction.